Value of p53 sequencing in the prognostication of head and neck cancer: a systematic review and meta-analysis
Abstract This review aimed to examine the relationship between TP53 mutational status, as determined by genomic sequencing, and survival in squamous cell carcinoma of the head and neck. The databases Medline, Embase, Web of Science (core collection), Scopus and Cochrane Library were searched from in...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2022-12-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-022-25291-2 |
| _version_ | 1797985591067934720 |
|---|---|
| author | Shadi Basyuni Gareth Nugent Ashley Ferro Eleanor Barker Ian Reddin Oliver Jones Matt Lechner Ben O’Leary Terry Jones Liam Masterson Tim Fenton Andrew Schache |
| author_facet | Shadi Basyuni Gareth Nugent Ashley Ferro Eleanor Barker Ian Reddin Oliver Jones Matt Lechner Ben O’Leary Terry Jones Liam Masterson Tim Fenton Andrew Schache |
| author_sort | Shadi Basyuni |
| collection | DOAJ |
| description | Abstract This review aimed to examine the relationship between TP53 mutational status, as determined by genomic sequencing, and survival in squamous cell carcinoma of the head and neck. The databases Medline, Embase, Web of Science (core collection), Scopus and Cochrane Library were searched from inception to April 2021 for studies assessing P53 status and survival. Qualitative analysis was carried out using the REMARK criteria. A meta-analyses was performed and statistical analysis was carried out to test the stability and reliability of results. Twenty-five studies met the inclusion criteria, of which fifteen provided enough data for quantitative evaluation. TP53 mutation was associated with worse overall survival (HR 1.75 [95% CI 1.45–2.10], p < 0.001), disease-specific survival (HR 4.23 [95% CI 1.19–15.06], p = 0.03), and disease-free survival (HR 1.80 [95% CI 1.28–2.53], p < 0.001). Qualitative assessment identified room for improvement and the pooled analysis of all anatomical subsites leads to heterogeneity that may erode the validity of the observed overall effect and its subsequent extrapolation and application to individual patients. Our systematic review and meta-analysis supports the utility of TP53 mutational as a prognostic factor for survival in head and neck squamous cell carcinoma. A well designed prospective, multi-centre trial is needed to definitively answer this question. |
| first_indexed | 2024-04-11T07:19:33Z |
| format | Article |
| id | doaj.art-0dd581c0a5274b41a285284df26b6703 |
| institution | Directory Open Access Journal |
| issn | 2045-2322 |
| language | English |
| last_indexed | 2024-04-11T07:19:33Z |
| publishDate | 2022-12-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj.art-0dd581c0a5274b41a285284df26b67032022-12-22T04:37:48ZengNature PortfolioScientific Reports2045-23222022-12-0112111310.1038/s41598-022-25291-2Value of p53 sequencing in the prognostication of head and neck cancer: a systematic review and meta-analysisShadi Basyuni0Gareth Nugent1Ashley Ferro2Eleanor Barker3Ian Reddin4Oliver Jones5Matt Lechner6Ben O’Leary7Terry Jones8Liam Masterson9Tim Fenton10Andrew Schache11Genomics England Head and Neck Cancer Clinical Interpretation PartnershipGenomics England Head and Neck Cancer Clinical Interpretation PartnershipDepartment of Oral and Maxillo-Facial Surgery, Cambridge University HospitalsMedical Library, School of Clinical Medicine, University of CambridgeGenomics England Head and Neck Cancer Clinical Interpretation PartnershipGenomics England Head and Neck Cancer Clinical Interpretation PartnershipGenomics England Head and Neck Cancer Clinical Interpretation PartnershipGenomics England Head and Neck Cancer Clinical Interpretation PartnershipGenomics England Head and Neck Cancer Clinical Interpretation PartnershipGenomics England Head and Neck Cancer Clinical Interpretation PartnershipGenomics England Head and Neck Cancer Clinical Interpretation PartnershipGenomics England Head and Neck Cancer Clinical Interpretation PartnershipAbstract This review aimed to examine the relationship between TP53 mutational status, as determined by genomic sequencing, and survival in squamous cell carcinoma of the head and neck. The databases Medline, Embase, Web of Science (core collection), Scopus and Cochrane Library were searched from inception to April 2021 for studies assessing P53 status and survival. Qualitative analysis was carried out using the REMARK criteria. A meta-analyses was performed and statistical analysis was carried out to test the stability and reliability of results. Twenty-five studies met the inclusion criteria, of which fifteen provided enough data for quantitative evaluation. TP53 mutation was associated with worse overall survival (HR 1.75 [95% CI 1.45–2.10], p < 0.001), disease-specific survival (HR 4.23 [95% CI 1.19–15.06], p = 0.03), and disease-free survival (HR 1.80 [95% CI 1.28–2.53], p < 0.001). Qualitative assessment identified room for improvement and the pooled analysis of all anatomical subsites leads to heterogeneity that may erode the validity of the observed overall effect and its subsequent extrapolation and application to individual patients. Our systematic review and meta-analysis supports the utility of TP53 mutational as a prognostic factor for survival in head and neck squamous cell carcinoma. A well designed prospective, multi-centre trial is needed to definitively answer this question.https://doi.org/10.1038/s41598-022-25291-2 |
| spellingShingle | Shadi Basyuni Gareth Nugent Ashley Ferro Eleanor Barker Ian Reddin Oliver Jones Matt Lechner Ben O’Leary Terry Jones Liam Masterson Tim Fenton Andrew Schache Value of p53 sequencing in the prognostication of head and neck cancer: a systematic review and meta-analysis Scientific Reports |
| title | Value of p53 sequencing in the prognostication of head and neck cancer: a systematic review and meta-analysis |
| title_full | Value of p53 sequencing in the prognostication of head and neck cancer: a systematic review and meta-analysis |
| title_fullStr | Value of p53 sequencing in the prognostication of head and neck cancer: a systematic review and meta-analysis |
| title_full_unstemmed | Value of p53 sequencing in the prognostication of head and neck cancer: a systematic review and meta-analysis |
| title_short | Value of p53 sequencing in the prognostication of head and neck cancer: a systematic review and meta-analysis |
| title_sort | value of p53 sequencing in the prognostication of head and neck cancer a systematic review and meta analysis |
| url | https://doi.org/10.1038/s41598-022-25291-2 |
| work_keys_str_mv | AT shadibasyuni valueofp53sequencingintheprognosticationofheadandneckcancerasystematicreviewandmetaanalysis AT garethnugent valueofp53sequencingintheprognosticationofheadandneckcancerasystematicreviewandmetaanalysis AT ashleyferro valueofp53sequencingintheprognosticationofheadandneckcancerasystematicreviewandmetaanalysis AT eleanorbarker valueofp53sequencingintheprognosticationofheadandneckcancerasystematicreviewandmetaanalysis AT ianreddin valueofp53sequencingintheprognosticationofheadandneckcancerasystematicreviewandmetaanalysis AT oliverjones valueofp53sequencingintheprognosticationofheadandneckcancerasystematicreviewandmetaanalysis AT mattlechner valueofp53sequencingintheprognosticationofheadandneckcancerasystematicreviewandmetaanalysis AT benoleary valueofp53sequencingintheprognosticationofheadandneckcancerasystematicreviewandmetaanalysis AT terryjones valueofp53sequencingintheprognosticationofheadandneckcancerasystematicreviewandmetaanalysis AT liammasterson valueofp53sequencingintheprognosticationofheadandneckcancerasystematicreviewandmetaanalysis AT timfenton valueofp53sequencingintheprognosticationofheadandneckcancerasystematicreviewandmetaanalysis AT andrewschache valueofp53sequencingintheprognosticationofheadandneckcancerasystematicreviewandmetaanalysis |